The case for & against
Bull & Bear analysis
Bullish
LivaNova PLC (LIA/LIVN) is a leading global medical technology company specializing in the development of innovative solutions for cardiac and neuromodulation therapies. With a strong focus on high-growth areas like cardiopulmonary and neuromodulation, LivaNova is positioning itself at the forefront of the medical technology sector. The company's commitment to enhancing patient outcomes through technology and innovation facilitates its competitive edge within the healthcare industry.
Bull says
- ↑Q2 2026 record revenue and earnings fueled by cardiopulmonary segment
- ↑Piper Sandler maintained Overweight and raised price target to $90
- ↑Raised full-year 2026 adjusted diluted EPS guidance after beat
- ↑Higher allocation to innovation and IT trims near-term FCF but fuels future returns
- ↑High earnings yield plus strong profitability and ROE signal undervaluation
- ↑Positive momentum factors and favorable moving averages support continued upside
Bear says
- ↓Multiple insider stock sales may signal management doubts
- ↓Shares slid with healthcare selloff driven by cyberattack and oil worries
- ↓Adjusted free cash flow guidance cut due to ramped innovation spending
- ↓Performance tied to external factors like regulation and economic shifts
- ↓Negative sales growth expectations and high short interest heighten downside risk
- ↓Weak profitability scores and elevated leverage risk increase vulnerability